Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/59466
Tipo: Artigo de Periódico
Título: Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Autor(es): Gustavo Fernandes
Daniel Girardi
João Paulo Bernardes
Felipe Paiva Fonseca
Eduardo Fregnani
Resumen: Background: Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case presentation: We present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy. Conclusion: This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.
Asunto: Ameloblastoma
Neoplasms
Mandible
Idioma: eng
País: Brasil
Editor: Universidade Federal de Minas Gerais
Sigla da Institución: UFMG
Departamento: FAO - DEPARTAMENTO DE CLÍNICA
Tipo de acceso: Acesso Aberto
Identificador DOI: https://doi.org/10.1186%2Fs12885-018-4802-y
URI: http://hdl.handle.net/1843/59466
Fecha del documento: 12-sep-2018
metadata.dc.url.externa: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134697/
metadata.dc.relation.ispartof: BMC Cancer
Aparece en las colecciones:Artigo de Periódico



Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.